Abstract:Every year, Candida, Aspergillus, Cryptococcus and Pneumocystis infect an estimated two million individuals worldwide. Most are immunocompromised or critically ill. Candida is the most common fungal pathogen of the critically ill and of recipients of transplanted abdominal organs. In high-risk haemato-oncological patients, in contrast, the introduction of antifungal prophylaxis with fluconazole and later with mould-active posaconazole has led to a remarkable reduction of invasive candidiasis and is likely to have a similar effect on invasive aspergillosis. Invasive aspergillosis remains the dominant invasive fungal disease (IFD) of haemato-oncological patients and solid-organ transplant recipients and is increasingly found in individuals with exacerbated chronic obstructive pulmonary disease on corticosteroids. In the developed world, owing to antiretroviral therapy Pneumocystis pneumonia and cryptococcosis have become rare in patients with human immunodeficiency virus (HIV) and are mainly found in solid-organ transplant recipients or immunocompromised patients. In the developing world, cryptococcosis remains a common and highly lethal disease of HIV positive individuals. With invasive candidiasis and invasive aspergillosis, timely diagnosis is the principal challenge. The clinical presentation is nonspecific and current diagnostic tests lack sensitivity and specificity. The combination of several tests improves sensitivity, but not specificity. Standardised polymerase chain-reaction-based assays may be promising tools for more rapid and specific diagnosis of candidiasis and invasive aspergillosis. Nevertheless, initiation of treatment is often based solely on clinical suspicion. Empirical therapy, however, may lead to over-treatment of patients without IFD or it may miss its target in the case of resistance. Despite the success of antifungal prophylaxis in reducing the incidence of IFDs in haemato-oncological patients, there are a considerable number of breakthrough infections demonstrating not only fungal resistance but also the emergence of rare and often lethal fungal pathogens. Knowledge of the local epidemiology and antifungal resistance is therefore pivotal. Current trial-based guidelines leave major gaps in identifying those most at risk, who may benefit from prophylaxis. Ongoing searches for disease-associated genetic polymorphisms may contribute to the establishment of individual risk profiles and targeted prophylaxis.

When the Fight Against Fungi Goes Wrong

Advances in Understanding Human Genetic Variations That Influence Innate Immunity to Fungi

The pathobiology of human fungal infections

DIAGNOSIS AND PREVENTION OF INVASIVE FUNGAL INFECTIONS IN THE IMMUNOCOMPROMISED HOST

Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia

Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions

Advanced genetic techniques in fungal pathogen research

A Human Commensal-Pathogenic Fungus Suppresses Host Immunity Via Targeting TBK1

Cutaneous and subcutaneous fungal infections: recent developments on host-fungus interactions

Fungal Primary and Opportunistic Pathogens: an Ecological Perspective.

Immune Interactions with Pathogenic and Commensal Fungi

Antifungal Innate Immunity: A Perspective from the Last 10 Years

Immunity to fungi and vaccine considerations

Monogenetic Causes of Fungal Disease: Recent Developments.

Advances in research on immunology of fungal infection

Invasive fungal pathogens from the tropical and temperate areas – a challenge in pathology and diagnosis

Basic Genetics and Immunology of Candida Infections

Antagonistic Changes in Sensitivity to Antifungal Drugs by Mutations of an Important ABC Transporter Gene in a Fungal Pathogen

Studying fungal pathogens of humans and fungal infections: fungal diversity and diversity of approaches

Autoimmune Diseases and Fungal Infections: Immunological Mechanisms and Therapeutic Approaches.

Invasive Fungal Infection in Primary Immunodeficiencies Other Than Chronic Granulomatous Disease